CROs/Service Providers

INC Research to manage Leukemia & Lymphoma Society umbrella trial

Friday, November 11, 2016

INC Research, a global phase I to IV CRO, has announced its involvement in The Leukemia & Lymphoma Society’s (LLS) recently-launched precision medicine Master Trial to treat acute myeloid leukemia (AML). The Beat AML Master Trial is breaking ground in a number of areas, including the first time a nonprofit organization is working with multiple biotech and pharma sponsors and other key collaborators to professionally operationalize a study. The trial will provide principal investigators and their patients consolidated access to test novel therapies matched to specific molecular aberrations in AML.

[Read More]

CiToxLAB acquires AccelLAB, a preclinical medical devices CRO

Wednesday, November 9, 2016

CiToxLAB, a preclinical CROs, has announced the acquisition of AccelLAB, a Canadian CRO specialized in the preclinical assessment of new medical devices. Through this acquisition, CiToxLAB Group reinforces its position in the non-clinical CRO arena and enlarges its services portfolio to medical devices, a fast growing area which offers large synergies with drug development, the CiToxLAB’s core business.

[Read More]

Envigo launches hepatotoxicity testing for drug development de-risking program

Monday, November 7, 2016

Envigo has launched an integrated program of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI)—one of the major causes of drugs being withdrawn from the market. Since 1980, over 30 drugs have been withdrawn because of hepatotoxicity with many others having severe restrictions placed upon their use. As a consequence, and to help minimize any risks to patients taking their medicines, the pharma industry is concerned not to progress compounds that show any potential DILI liability.

[Read More]

Report: Nine evidence-based approaches to transform drug development and commercialization

Monday, October 31, 2016

Life sciences companies increasingly are seeking new models to connect expanding sets of disparate, non-identified patient-level data streams to better develop and commercialize next-generation medicines. The need for practical, evidence-based approaches is especially acute at a time when scientific advances, the growing need for new medicines, and constrained budgets for healthcare and other social services are colliding.

[Read More]

ICON, TriNetX partner

Monday, October 31, 2016

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has further improved its feasibility, protocol optimization and patient recruitment capabilities through the use of TriNetX.

[Read More]

Q2 Solutions, Illumina collaborate, enhance companion diagnostics capabilities

Monday, October 31, 2016

Q2 Solutions, a global clinical trials laboratory services organization, has announced the expansion of its genomic companion diagnostics (CDx) capabilities. This comes as a result of an agreement between Q2 Solutions—EA Genomics and Illumina, a global leader in genomics, to establish a framework for developing next-generation sequencing-based (NGS) CDx assays. The expansion of Q2 Solutions’ CDx development portfolio will further enhance the company’s wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.

[Read More]

FMD K&L merged with iMEDGlobal

Monday, October 24, 2016

FMD K&L and iMEDGlobal  have entered into a merger agreement. FMD K&L is a privately owned CRO with headquarters in the U.S. and China. iMEDGlobal is a privately owned CRO with headquarters in the U.S. and with main delivery centers in India and the Philippines.

[Read More]

Lovelace Biomedical launches as preclinical CRO

Monday, October 24, 2016

Lovelace Biomedical, a not-for-profit preclinical contract research organization, has launched and offers toxicology, pharmacology and other services to pharmaceutical and biotechnology companies. It will partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, with services and expertise spanning the fields of respiratory disease, infectious disease, gene therapy, neuroscience, alternative tobacco products and medical countermeasures, as well as drug discovery and others.

[Read More]